Genomic mutations in patients with advanced non-small cell lung cancer in Yunan and its clinical significance
DOI：10.3872/j.issn.1007-385x.2021.04.008
- VernacularTitle:云南地区晚期非小细胞肺癌患者的基因突变及其临床意义
- Author:
MO Xin
1
,
2
;
WU Maofang
1
,
2
;
CAI Jingjing
1
,
2
;
MAO Jiahui
1
,
2
;
LI Yingwei
1
,
2
;
ZHOU Yongchun
1
,
2
Author Information
1. Joint International Cooperation Laboratory of Plateau Regional High-incidence Cancer, Key Laboratory of Lung Cancer Research of Yunnan Province, the Third Affiliated Hospital of Kunming Medical University &
2. Yunnan Cancer Hospital, Kunming 650118, Yunnan, China
- Publication Type:Clinical Trial
- Keywords:
non-small cell lung cancer (NSCLC);
next generation sequencing (NGS);
epidermal growth factor receptor (EGFR);
genetic mutation
- From:
Chinese Journal of Cancer Biotherapy
2021;28(4):365-369
- CountryChina
- Language:Chinese
-
Abstract:
[Abstract] Objective: To investigate the lung cancer-associated driver gene mutations in peripheral blood of patients with advanced non-small cell lung cancer (NSCLC) in Yunnan area, and to explore their association with clinical pathological features. Methods: Peripheral blood of 304 patients with stage Ⅳ NSCLC were collected from Molecular Diagnostic Center of Yunnan Cancer Hospital during January 2019 to December 2019. Next generation sequencing (NGS) technique was used to detect the mutation of NSCLC related driver genes, chi-square test was used to analyze the relationship between the major mutant genes and the clinicopathological features of patients, and Logistic regression was used to analyze the independent risk factors. Results: In the peripheral blood of 304 patients with stage Ⅳ NSCLC, there were 120 (39.47%) cases with EGFR mutations, 12 (3.95%) cases with ALK fusion, 36 (11.84%) case with other mutations such as KRAS, BRAF and RET. The main EGFR mutations were 19del and L858R (69.17%). The mutation rate of EGFR was higher in female, young, non-smoking, non-chemotherapy and lung adenocarcinoma patients (49.26% vs 31.55%, 45.39% vs 33.56%, 45.92% vs 27.78%, 45.07% vs 26.37%, 42.39% vs 10.71%, all P<0.05). Multivariate analysis showed that female, no history of chemotherapy and lung adenocarcinoma were independent risk factors for EGFR mutations (all P<0.05). Conclusion: Using NGS technology to detect the driver genes in peripheral blood of patients with advanced NSCLC in Yunnan area showed that the mutation rate of EGFR was higher in women and lung adenocarcinoma patients without chemotherapy history.
- Full text:20210408.pdf
